Bispecific engager-secreting TIL therapy
/ Grit Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 03, 2025
A Bispecific Engager-Secreting TIL Therapy Designed to Penetrate Stromal Barriers and Boost Tumor Killing in Solid Tumors
(SITC 2025)
- "By enhancing tumor infiltration and harnessing both engineered and endogenous T cells, RD213 represents a novel TIL-based therapeutic strategy for the treatment of refractory solid tumors. Clinical development of RD213 is currently underway."
Stroma • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1